Pragma Pharmaceuticals Announces Re-Launch of Moxatag®

Pragma acquired Moxatag from Shionogi Inc in March 2014 and has been working to make the product available in time for the upcoming cold and flu season.

PRESS RELEASE

NEW YORK—August 14, 2014

Pragma Pharmaceuticals is pleased to announce that it is re-launching Moxatag® 775 mg (amoxicillin extended-release tablets), the only once-a-day amoxicillin.

Pragma acquired Moxatag from Shionogi Inc. in March 2014 and has been working to make the product available in time for the upcoming cold and flu season.

A Pragma spokesperson says, "Amoxicillin is the gold standard in treating strep pharyngitis. Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy."

Fera Pharmaceuticals has been selected to manage the sales and marketing of Moxatag for Pragma.

About Moxatag

Moxatag, the first and only once-a-day amoxicillin, is indicated for the treatment of tonsillitis and/or pharyngitis secondary to

Streptococcus pyogenes (S. pyogenes) in adult and pediatric patients 12 years of age or older. For more information visit www.moxatag.com.

Contact:

Louis B. DellaFera, Pharm. D.

516-209-5978

Louis@pragmapharma.com